This possibility is supported by our observation that T-cell mediated anti-CMT.64 tumor immunity can be augmented by B7.1 expressing tumor cells compared with B7.1 negative tumor cells (Fig. 2C left). The gene discussed is CD80; the disease is neoplasm.